Clinical trial · no report yet · Phase 3
NCT06711900
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- NCT06711900 ↗
- Active, not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- SKB264; Pembrolizumab; pemetrexed; carboplatin or cisplatin
- Arms
- SKB264+Pembrolizumab · Experimental
- Pembrolizumab+Chemotherapy · Active comparator
- Enrollment
- 432 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Oct 30, 2024
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06711900 · updated Jul 8, 2026